PTC THERAPEUTICS INC (PTCT) Stock Price, Quote, News and Overview
NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD
PTCT Quote, Performance and Key Statistics
44.74
-1.58 (-3.41%)
The current stock price of PTCT is 44.74 USD. In the past month the price decreased by -9.71%. In the past year, price increased by 31.24%.
PTCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.53 | 336.11B | ||
| AMGN | AMGEN INC | 14.77 | 164.85B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
| ARGX | ARGENX SE - ADR | 102.95 | 36.15B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
| INSM | INSMED INC | N/A | 19.72B | ||
| BIIB | BIOGEN INC | 8.31 | 19.27B |
Related stock screener links
About PTCT
Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Company Info
PTC THERAPEUTICS INC
500 Warren Corporate Center Drive
WARREN NEW JERSEY 07080 US
CEO: Stuart W. Peltz
Employees: 939
Phone: 19082227000
PTC THERAPEUTICS INC / PTCT FAQ
What is the stock price of PTC THERAPEUTICS INC today?
The current stock price of PTCT is 44.74 USD. The price decreased by -3.41% in the last trading session.
What is the ticker symbol for PTC THERAPEUTICS INC stock?
The exchange symbol of PTC THERAPEUTICS INC is PTCT and it is listed on the Nasdaq exchange.
On which exchange is PTCT stock listed?
PTCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PTC THERAPEUTICS INC stock?
23 analysts have analysed PTCT and the average price target is 63.78 USD. This implies a price increase of 42.57% is expected in the next year compared to the current price of 44.74. Check the PTC THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PTC THERAPEUTICS INC worth?
PTC THERAPEUTICS INC (PTCT) has a market capitalization of 3.55B USD. This makes PTCT a Mid Cap stock.
How many employees does PTC THERAPEUTICS INC have?
PTC THERAPEUTICS INC (PTCT) currently has 939 employees.
What are the support and resistance levels for PTC THERAPEUTICS INC (PTCT) stock?
PTC THERAPEUTICS INC (PTCT) has a support level at 44.73 and a resistance level at 47.39. Check the full technical report for a detailed analysis of PTCT support and resistance levels.
Is PTC THERAPEUTICS INC (PTCT) expected to grow?
The Revenue of PTC THERAPEUTICS INC (PTCT) is expected to grow by 115.74% in the next year. Check the estimates tab for more information on the PTCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PTC THERAPEUTICS INC (PTCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PTCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PTCT, evaluating the profitability, health, valuation and growth aspects
- PTC THERAPEUTICS INC (PTCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PTC THERAPEUTICS INC (PTCT) Sales and EPS estimates to see what analysts future expectations are.
- PTC THERAPEUTICS INC (PTCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PTC THERAPEUTICS INC (PTCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- PTC THERAPEUTICS INC (PTCT) Stock Chart to make your own analysis
- PTC THERAPEUTICS INC (PTCT) Latest news and press-releases to stay up to date.
Does PTC THERAPEUTICS INC (PTCT) stock pay dividends?
PTCT does not pay a dividend.
When does PTC THERAPEUTICS INC (PTCT) report earnings?
PTC THERAPEUTICS INC (PTCT) will report earnings on 2025-07-31, after the market close.
What is the Price/Earnings (PE) ratio of PTC THERAPEUTICS INC (PTCT)?
The PE ratio for PTC THERAPEUTICS INC (PTCT) is 8.55. This is based on the reported non-GAAP earnings per share of 5.23 and the current share price of 44.74 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTCT.
What is the Short Interest ratio of PTC THERAPEUTICS INC (PTCT) stock?
The outstanding short interest for PTC THERAPEUTICS INC (PTCT) is 7.76% of its float. Check the ownership tab for more information on the PTCT short interest.
PTCT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT turns out to be only a medium performer in the overall market: it outperformed 62.8% of all stocks.
PTCT Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PTCT. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here.
PTCT Financial Highlights
Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of 5.23. The EPS increased by 189.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.55% | ||
| ROA | 22.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to PTCT. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of 215.08% and a revenue growth 115.74% for PTCT